- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06314399
Predictive Factors Associated to Bile Cultures and Antibiogram Resistance in Patients with Laparoscopic Cholecystectomy (BACILO)
March 14, 2025 updated by: Camilo Ramirez Giraldo, Hospital Universitario Mayor Méderi
Predictive Factors Associated with Bile Culture Positivity and PhenotypiCal AntIbiogram Resistance Patterns in Patients Taken to LaparOscopic Cholecystectomy (BACILO): a Protocol for a Prediction Model Study
The BACILO study was designed with the objective of having robust data on local epidemiological bacterial colonisation information on bile cultures with patients taken to laparoscopic cholecystectomy in our institution to find which predictive factors are associated with culture positivity and antibiotic resistance patterns.
Secondary endpoints include evaluating demographical, clinical and surgical variables and establishing comparison between both positive and negative bile cultures and between antibiotic sensitive and resistant microorganism strain isolations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
BACILO is single-centre, observational, analytical, prospective study with a prognostic prediction model with the objective of identifying predictive factors associated with microbial and antibiotic resistance patterns in bile cultures of patients taken to laparoscopic cholecystectomy in our institution.
Primary outcomes are bile culture positivity and phenotypical resistance antibiogram patterns while secondary outcomes include demographic, clinical and surgical characteristics and surgical outcomes.
The main objective is to determine predictive factors using a prediction model, variables included are: Age, diabetes mellitus, C-reactive protein test, choledocholithiasis/ERCP, cholecystitis and severity of cholecystitis according to the 2018 Tokyo guidelines.This in the nature of describing the relationship between bile culture positivity and phenotypical antibiogram resistance patterns in our institution, and establish thus better treatment strategies based on higher quality local evidence.
Study Type
Observational
Enrollment (Actual)
703
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111221
- Hospital Universitario Mayor-Méderi
-
Bogota, Cundinamarca, Colombia, 111221
- Hospital Universitario Méderi Barrios Unidos
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients that are over 18 years that have an indication for laparoscopic cholecystectomy in our institution without any of the exclusion criteria, which had bile cultures taken from the surgical specimen (gallbladder) during the surgery and attended the postoperative15 day follow-up appointment after hospital discharge.
Description
Inclusion Criteria:
- Patients included must be over 18 years of age and be taken to laparoscopic cholecystectomy between March 2024 and February 2026 in any institution of the Méderi hospital network (Hospital Universitario Mayor and Hospital Universitario Barrios Unidos), have signed the written informed consent to be included in the study and have both bile culture and antibiogram.
Exclusion Criteria:
- - Patients that will be taken to laparoscopic cholecystectomy with another concomitant surgical procedure (including but not exclusive to gastrectomy, pancreatoduodenectomy, oesophagectomy, splenectomy, abdominal wall reconstruction, colectomy, amongst others) with the exception of umbilical herniorrhaphy.
- Patients without a postoperative control appointment.
- Patients with an untreated HIV diagnosis.
- Patients with diagnosis of a malignant gallbladder or biliary tract disease documented preoperatively.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bile culture positivity
Time Frame: Perioperatively, during the procedure and immediately after the intervention
|
Bile culture is tested positive for at least one (1) microorganism
|
Perioperatively, during the procedure and immediately after the intervention
|
|
Phenotypical antibiogram resistance
Time Frame: Perioperatively, during the procedure and immediately after the intervention
|
If bile culture is positive, evaluation for possible antibiotic resistance vs sensitivity
|
Perioperatively, during the procedure and immediately after the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Microbial characteristics
Time Frame: Immediately after the intervention
|
To describe the microbial characteristics of the bile cultures and their phenotypical antibiogram resistance
|
Immediately after the intervention
|
|
Bile culture and antibiotic resistance relationship
Time Frame: Immediately after the intervention
|
Explore the relationship between positive bile cultures and phenotypical antibiogram resistance with surgical outcomes
|
Immediately after the intervention
|
|
Demographical and clinical characteristics
Time Frame: Pre-intervention
|
To describe and compare the demographic and clinical characteristics of the study population.
|
Pre-intervention
|
|
Surgical characteristics and outcomes
Time Frame: During the 15 day postoperative follow-up appointment
|
To describe and compare the surgical characteristics and outcomes of the study population
|
During the 15 day postoperative follow-up appointment
|
|
Determination of predictive factors (age, diabetes mellitus, choledocholithiasis / ERCP, C-reactive protein, cholecystitis and Tokyo guidelines severity of cholecystitis)
Time Frame: Through study completion, around 1 year and a half
|
To determine demographic and clinical predictive factors for positive bile cultures and phenotypical antibiogram resistance.
|
Through study completion, around 1 year and a half
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Galili O, Eldar S Jr, Matter I, Madi H, Brodsky A, Galis I, Eldar S Sr. The effect of bactibilia on the course and outcome of laparoscopic cholecystectomy. Eur J Clin Microbiol Infect Dis. 2008 Sep;27(9):797-803. doi: 10.1007/s10096-008-0504-8. Epub 2008 Mar 28.
- Gomi H, Solomkin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, Ukai T, Endo I, Iwashita Y, Hibi T, Pitt HA, Matsunaga N, Takamori Y, Umezawa A, Asai K, Suzuki K, Han HS, Hwang TL, Mori Y, Yoon YS, Huang WS, Belli G, Dervenis C, Yokoe M, Kiriyama S, Itoi T, Jagannath P, Garden OJ, Miura F, de Santibanes E, Shikata S, Noguchi Y, Wada K, Honda G, Supe AN, Yoshida M, Mayumi T, Gouma DJ, Deziel DJ, Liau KH, Chen MF, Liu KH, Su CH, Chan ACW, Yoon DS, Choi IS, Jonas E, Chen XP, Fan ST, Ker CG, Gimenez ME, Kitano S, Inomata M, Mukai S, Higuchi R, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):3-16. doi: 10.1002/jhbp.518. Epub 2018 Jan 9.
- Pisano M, Allievi N, Gurusamy K, Borzellino G, Cimbanassi S, Boerna D, Coccolini F, Tufo A, Di Martino M, Leung J, Sartelli M, Ceresoli M, Maier RV, Poiasina E, De Angelis N, Magnone S, Fugazzola P, Paolillo C, Coimbra R, Di Saverio S, De Simone B, Weber DG, Sakakushev BE, Lucianetti A, Kirkpatrick AW, Fraga GP, Wani I, Biffl WL, Chiara O, Abu-Zidan F, Moore EE, Leppaniemi A, Kluger Y, Catena F, Ansaloni L. 2020 World Society of Emergency Surgery updated guidelines for the diagnosis and treatment of acute calculus cholecystitis. World J Emerg Surg. 2020 Nov 5;15(1):61. doi: 10.1186/s13017-020-00336-x.
- Dyrhovden R, Ovrebo KK, Nordahl MV, Nygaard RM, Ulvestad E, Kommedal O. Bacteria and fungi in acute cholecystitis. A prospective study comparing next generation sequencing to culture. J Infect. 2020 Jan;80(1):16-23. doi: 10.1016/j.jinf.2019.09.015. Epub 2019 Oct 2.
- Yoon JH, Paik KY, Chung HY, Oh JS. Clinical implication of bactibilia in moderate to severe acute cholecystitis undergone cholecystostomy following cholecystectomy. Sci Rep. 2021 Jun 4;11(1):11864. doi: 10.1038/s41598-021-91261-9.
- van der Linden YT, Bosscha K, Prins HA, Lips DJ. Single-port laparoscopic cholecystectomy vs standard laparoscopic cholecystectomy: A non-randomized, age-matched single center trial. World J Gastrointest Surg. 2015 Aug 27;7(8):145-51. doi: 10.4240/wjgs.v7.i8.145.
- Wu ZY, Wu XS, Yao WY, Wang XF, Quan ZW, Gong W. [Pathogens' distribution and changes of antimicrobial resistance in the bile of acute biliary tract infection patients]. Zhonghua Wai Ke Za Zhi. 2021 Jan 1;59(1):24-31. doi: 10.3760/cma.j.cn112139-20200717-00559. Chinese.
- Manrai M, Jha AA, Singh Shergill SP, Thareja S, Sood AK, Shukla R, Jain R, Dhiman P, Gaurab. Microbiology of bile in extrahepatic biliary obstruction: A tropical experience. Indian J Med Microbiol. 2021 Jan;39(1):54-58. doi: 10.1016/j.ijmmb.2020.10.002. Epub 2020 Dec 4.
- Lee JM, Kang JS, Choi YJ, Byun Y, Jin SH, Yoon KC, Lee HW, Jang JY, Lim CS. Suggested use of empirical antibiotics in acute cholecystitis based on bile microbiology and antibiotic susceptibility. HPB (Oxford). 2023 May;25(5):568-576. doi: 10.1016/j.hpb.2023.01.017. Epub 2023 Feb 3.
- Kaplan U, Handler C, Chazan B, Weiner N, Hatoum OA, Yanovskay A, Kopelman D. The Bacteriology of Acute Cholecystitis: Comparison of Bile Cultures and Clinical Outcomes in Diabetic and Non-Diabetic Patients. World J Surg. 2021 Aug;45(8):2426-2431. doi: 10.1007/s00268-021-06107-2. Epub 2021 Apr 15.
- Shafagh S, Rohani SH, Hajian A. Biliary infection; distribution of species and antibiogram study. Ann Med Surg (Lond). 2021 Sep 7;70:102822. doi: 10.1016/j.amsu.2021.102822. eCollection 2021 Oct.
- Jang DK, Kim J, Park WB, Yi SY, Lee JK, Yoon WJ. Increasing burden of biliary tract infection caused by extended-spectrum beta-lactamase-producing organisms in Korea: A nationwide population-based study. J Gastroenterol Hepatol. 2020 Jan;35(1):56-64. doi: 10.1111/jgh.14809. Epub 2019 Aug 13.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2024
Primary Completion (Actual)
October 26, 2024
Study Completion (Actual)
December 24, 2024
Study Registration Dates
First Submitted
March 8, 2024
First Submitted That Met QC Criteria
March 13, 2024
First Posted (Actual)
March 18, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
March 14, 2025
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-18
- DVO005 2555-CV1837 (Other Identifier: Universidad del Rosario Research Ethics Committee)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data obtained and input into the database is anonymous, without any individual or identifying characteristics will be stored in a dataset from the Centro de Recursos para el Aprendizaje y la Investigación, property of and administered by the Universidad del Rosario as a plan of data management.
Moreover, the different codes used in the analysis will be stored in this dataset.
IPD Sharing Time Frame
It is in our plans once we obtain a register number from Clinical Trials in order to publish the protocol, statistical analysis plan and clinical study report in a scientific journal so it will be available to all people interested.
IPD Sharing Access Criteria
It is in our plans to be published in a scientific journal available to all people interested.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antibiotic Resistant Strain
-
Federal Research Institute of Pediatric Hematology...Not yet recruitingAntibiotic Resistant StrainRussian Federation
-
Cairo UniversityNot yet recruitingAntibiotic Resistant StrainEgypt
-
Assistance Publique - Hôpitaux de ParisRecruitingAntibiotic Resistant Strain | Transmission, Close-ContactFrance
-
Microbiome Health Research InstituteUniversity of Wisconsin, Madison; Indiana UniversityCompletedAntibiotic Resistant StrainUnited States
-
Microbiome Health Research InstituteBoston Medical CenterCompletedAntibiotic Resistant StrainUnited States
-
Kangdong Sacred Heart HospitalCompletedHelicobacter Pylori Infection | Antibiotic Resistant Strain
-
Lund UniversityCompletedTraveler's Diarrhea | Antibiotic Resistant Infection | Antibiotic Resistant StrainSweden
-
University of Novi SadActive, not recruitingPostoperative Complications | Infection, Bacterial | Antibiotic Side Effect | Antibiotic Resistant Infection | Antibiotic Resistant Strain | Antibiotic Reaction | Infection, LaboratorySerbia
-
Rambam Health Care CampusTel-Aviv Sourasky Medical CenterCompletedMicrobial Colonization | Antibiotic Resistant StrainIsrael
-
Rambam Health Care CampusWithdrawnMicrobial Colonization | Antibiotic Resistant StrainIsrael
Clinical Trials on Bile culture and phenotypic antibiogram resistance test
-
Gaffree & Guinle Universitary HospitalCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional...RecruitingDegenerative Disc Disease | Back Pain, LowBrazil
-
Hospital Son EspasesUnknownCholelithiasis | Gall Bladder Disease | Gall StoneSpain
-
Seoul National University HospitalActive, not recruitingAcute CholangitisKorea, Republic of
-
Mayo ClinicSatiogen Pharmaceuticals, Inc.CompletedOverweight | Type 2 Diabetes Mellitus | ObeseUnited States
-
Safaa SamirUnknown
-
Origio A/SCompletedInfertilityDenmark, Sweden
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingTuberculosis, Pulmonary
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingCarbapenem-Resistant Enterobacteriaceae InfectionItaly
-
PathnosticsComprehensive Urology-a Division of Michigan Healthcare ProfessionalsCompletedUrinary Tract Infections | Interstitial Cystitis | ProstatitisUnited States